JPWO2020201038A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020201038A5 JPWO2020201038A5 JP2021557778A JP2021557778A JPWO2020201038A5 JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5 JP 2021557778 A JP2021557778 A JP 2021557778A JP 2021557778 A JP2021557778 A JP 2021557778A JP WO2020201038 A5 JPWO2020201038 A5 JP WO2020201038A5
- Authority
- JP
- Japan
- Prior art keywords
- lipocalin mutein
- lipocalin
- medicament according
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
用語「約(about)」または「約(approximately)」は、本明細書において使用される場合、所与の値または範囲から20％以内、好ましくは10％以内、およびより好ましくは5％以内を意味する。しかし、この用語は、実際の値もまた含み、例えば「約20」は20を含む。
[本発明1001]
対象にリポカリンムテインを投与する方法であって、吸入によってリポカリンムテインを投与する段階を含み、該投与が、気道における該リポカリンムテインへの局所曝露をもたらす、方法。
[本発明1002]
対象の治療法における使用のためのリポカリンムテインであって、該使用が、吸入によってリポカリンムテインを投与することを含み、該投与が、気道における該リポカリンムテインへの局所曝露をもたらす、使用のためのリポカリンムテイン。
[本発明1003]
リポカリンムテインの送達用量の約0.15％またはそれ未満が循環系に入る、本発明1001または1002の、方法、または使用のためのリポカリンムテイン。
[本発明1004]
リポカリンムテインの全身曝露が検出不可能である、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1005]
血液中への吸収によって全身曝露が定義される、本発明1004の、方法、または使用のためのリポカリンムテイン。
[本発明1006]
リポカリンムテインの送達用量が、投与1回につき約0.1mg～約1000mg、または投与1回につき体重1kg当たり約0.05μg～約15mgである、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1007]
リポカリンムテインの送達用量が、投与1回につき約0.1mg～約5mg、または投与1回につき体重1kg当たり約0.05μg～約50μgである、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1008]
前記方法または使用が、気道の疾患を治療するためである、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1009]
気道の疾患が、アレルギー性炎症、アレルギー性喘息、鼻炎、結膜炎、肺線維症、嚢胞性線維症、慢性閉塞性肺疾患、肺胞タンパク症、成人呼吸窮迫症候群、または細菌感染症である、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1010]
対象にリポカリンムテインを投与する方法であって、吸入によってリポカリンムテインを投与する段階を含み、該投与が、該リポカリンムテインの全身曝露をもたらす、方法。
[本発明1011]
対象の治療法における使用のためのリポカリンムテインであって、該使用が、吸入によってリポカリンムテインを投与することを含み、該投与が、該リポカリンムテインの全身曝露をもたらす、使用のためのリポカリンムテイン。
[本発明1012]
リポカリンムテインの送達用量の約0.3％もしくはそれより多く、約0.4％もしくはそれより多く、約0.5％もしくはそれより多く、約0.6％もしくはそれより多く、約0.7％もしくはそれより多く、約0.8％もしくはそれより多く、約0.9％もしくはそれより多く、約1％もしくはそれより多く、約2％もしくはそれより多く、約3％もしくはそれより多く、約4％もしくはそれより多く、約5％もしくはそれより多く、約6％もしくはそれより多く、約7％もしくはそれより多く、約8％もしくはそれより多く、約9％もしくはそれより多く、約10％もしくはそれより多く、約11％もしくはそれより多く、約12％もしくはそれより多く、約13％もしくはそれより多く、約14％もしくはそれより多く、または約15％もしくはそれより多くが循環系に入る、本発明1010または1011の、方法、または使用のためのリポカリンムテイン。
[本発明1013]
血漿中リポカリンムテインの最大濃度が、投与後約0.5時間～約10時間の時点で、好ましくは投与後約0.5時間～約4時間の時点で実現される、本発明1010～1012のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1014]
血漿中リポカリンムテインの最大濃度が、約1ng/mLもしくはそれより高く、好ましくは約1ng/mL～約2,000ng/mLである、本発明1010～1013のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1015]
リポカリンムテインが、投与1回につき約0.05mg～約1000mgまたは投与1回につき体重1kg当たり約0.1μg～約15mgの送達用量で投与される、本発明1010～1014のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1016]
リポカリンムテインが、投与1回につき約5mg～約1000mgまたは投与1回につき体重1kg当たり約0.1mg～約15mgの送達用量で投与される、本発明1010～1015のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1017]
リポカリンムテインの、ある期間にわたる血清中濃度の曲線下面積(AUC
inf
)が、約10h*ng/mLもしくはそれより大きく、例えば約10h*ng/mL～約16,000h*ng/mLである、本発明1010～1016のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1018]
リポカリンムテインが、約2時間～約10時間の血清半減期(t
1/2
)を有する、本発明1010～1017のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1019]
リポカリンムテインへの全身曝露が、同じまたは同程度の生体利用可能量のリポカリンムテインの全身投与と比べて改善された治療効果をもたらす、本発明1010～1018のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1020]
前記方法または使用が、気道の疾患を治療するためである、本発明1010～1019のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1021]
気道の疾患が、アレルギー性炎症、アレルギー性喘息、鼻炎、結膜炎、肺線維症、嚢胞性線維症、慢性閉塞性肺疾患、肺胞タンパク症、成人呼吸窮迫症候群、または細菌感染症である、本発明1010～1020のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1022]
前記方法または使用が、全身性疾患を治療するためである、本発明1010～1019のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1023]
前記方法または使用が、気道の疾患以外の、器官または組織を冒す疾患を治療するためである、本発明1010～1019のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1024]
前記方法または使用が、癌、貧血、疼痛性障害、炎症性疾患、心血管疾患、神経変性疾患、アレルギー性疾患、例えば、鼻炎、結膜炎、皮膚炎、もしくは食物アレルギー、または細菌感染症、例えば緑膿菌(Pseudomonas aeruginosa)感染症を治療するためである、本発明1010～1019、1022、および1023のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1025]
リポカリンムテインの効果の発現が、リポカリンムテインが皮下投与された場合の発現よりも速い、本発明1010～1024のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1026]
リポカリンムテインの効果の発現が、リポカリンムテインが全身投与された場合の発現とほぼ同じ速さであるかまたはそれよりも速い、本発明1010～1024のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1027]
FDKPと組み合わせたリポカリンムテインの効果の発現が、リポカリンムテインが吸入によって単独で投与された場合の発現とほぼ同じ速さであるかまたはそれよりも速い、本発明1010～1024のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1028]
投与が、1回、週に1回、週に2回、週に3回、週に4回、週に5回、週に6回、1日に1回、1日に2回である、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1029]
リポカリンムテインが噴霧形態で投与される、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1030]
リポカリンムテインが乾燥粉末として投与される、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1031]
リポカリンムテインが液状スプレーとして投与される、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1032]
リポカリンムテインがヒト対象に投与される、前記本発明のいずれかの、方法、または使用のためのリポカリンムテイン。
[本発明1033]
リポカリンムテインがヒト涙液リポカリン(hTlc)またはヒト好中球ゼラチナーゼ関連リポカリン(hNGAL)のムテインである、前記本発明のいずれかの方法、または使用のための組成物。
The terms "about" or "approximately" as used herein refer to within 20%, preferably within 10%, and more preferably within 5% of a given value or range. means. However, the term also includes the actual value, eg "about 20" includes 20.
[Invention 1001]
A method of administering a lipocalin mutein to a subject, comprising administering the lipocalin mutein by inhalation, said administration resulting in localized exposure to said lipocalin mutein in the respiratory tract.
[Invention 1002]
A lipocalin mutein for use in a method of treating a subject, said use comprising administering the lipocalin mutein by inhalation, said administration resulting in localized exposure to said lipocalin mutein in the respiratory tract. Lipocalin mutein.
[Invention 1003]
A lipocalin mutein for the method or use of invention 1001 or 1002, wherein about 0.15% or less of the delivered dose of the lipocalin mutein enters the circulation.
[Invention 1004]
A lipocalin mutein for any of the preceding methods, methods, or uses of the invention wherein systemic exposure of the lipocalin mutein is undetectable.
[Invention 1005]
A lipocalin mutein for the method or use of the invention 1004, wherein systemic exposure is defined by absorption into the blood.
[Invention 1006]
For any of the preceding methods, methods, or uses of the invention, wherein the delivered dose of the lipocalin mutein is from about 0.1 mg to about 1000 mg per administration, or from about 0.05 μg to about 15 mg per kg body weight per administration. Lipocalin mutein.
[Invention 1007]
for any of the preceding methods, methods, or uses of the invention, wherein the delivered dose of the lipocalin mutein is from about 0.1 mg to about 5 mg per administration, or from about 0.05 μg to about 50 μg per kg body weight per administration. Lipocalin mutein.
[Invention 1008]
A lipocalin mutein for the method or use of any of the preceding inventions, wherein the method or use is for treating a disease of the respiratory tract.
[Invention 1009]
The airway disease is allergic inflammation, allergic asthma, rhinitis, conjunctivitis, pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, alveolar proteinosis, adult respiratory distress syndrome, or bacterial infection, said A lipocalin mutein for any method, or use of the invention.
[Invention 1010]
A method of administering a lipocalin mutein to a subject, comprising administering the lipocalin mutein by inhalation, said administration resulting in systemic exposure of said lipocalin mutein.
[Invention 1011]
A lipocalin mutein for use in a method of treating a subject, said use comprising administering the lipocalin mutein by inhalation, said administration resulting in systemic exposure of said lipocalin mutein.
[Invention 1012]
about 0.3% or more, about 0.4% or more, about 0.5% or more, about 0.6% or more, about 0.7% or more, about 0.8% or more of the delivered dose of the lipocalin mutein more, about 0.9% or more, about 1% or more, about 2% or more, about 3% or more, about 4% or more, about 5% or more more than about 6% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 11% or more, About 12% or more, about 13% or more, about 14% or more, or about 15% or more of the method, or use of invention 1010 or 1011 enters the circulatory system. Lipocalin mutein for.
[Invention 1013]
any of the invention 1010-1012, wherein the maximum concentration of the lipocalin mutein in plasma is achieved at about 0.5 hours to about 10 hours after administration, preferably at about 0.5 hours to about 4 hours after administration; A lipocalin mutein for the method or use.
[Invention 1014]
for the method, or use of any of inventions 1010-1013, wherein the maximum plasma lipocalin mutein concentration is about 1 ng/mL or higher, preferably about 1 ng/mL to about 2,000 ng/mL Lipocalin mutein.
[Invention 1015]
The method, or use of any of Inventions 1010-1014, wherein the lipocalin mutein is administered at a delivered dose of from about 0.05 mg to about 1000 mg per administration or from about 0.1 μg to about 15 mg per kg body weight per administration. Lipocalin mutein for.
[Invention 1016]
The method, or use of any of Inventions 1010-1015, wherein the lipocalin mutein is administered at a delivered dose of about 5 mg to about 1000 mg per dose or about 0.1 mg to about 15 mg per kg body weight per dose. Lipocalin mutein for.
[Invention 1017]
The present invention wherein the lipocalin mutein has an area under the curve of serum concentration over time (AUC inf ) of about 10 h*ng/mL or greater, such as from about 10 h*ng/mL to about 16,000 h*ng/mL. A lipocalin mutein for the method or use of any of inventions 1010-1016.
[Invention 1018]
The lipocalin mutein for the method, or use of any of inventions 1010-1017, wherein the lipocalin mutein has a serum half-life (t 1/2 ) of from about 2 hours to about 10 hours.
[Invention 1019]
A method, or use of any of the Inventions 1010-1018, wherein systemic exposure to a lipocalin mutein results in an improved therapeutic effect compared to systemic administration of the same or comparable bioavailable amount of a lipocalin mutein lipocalin mutein.
[Invention 1020]
A lipocalin mutein for the method or use of any of the inventions 1010-1019, wherein said method or use is for treating a disease of the respiratory tract.
[Invention 1021]
The airway disease is allergic inflammation, allergic asthma, rhinitis, conjunctivitis, pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, alveolar proteinosis, adult respiratory distress syndrome, or bacterial infection. A lipocalin mutein for the method or use of any of inventions 1010-1020.
[Invention 1022]
A lipocalin mutein for the method or use of any of the inventions 1010-1019, wherein said method or use is for treating a systemic disease.
[Invention 1023]
A lipocalin mutein for the method or use of any of the inventions 1010-1019, wherein said method or use is for treating a disease affecting an organ or tissue other than a disease of the respiratory tract.
[Invention 1024]
Said method or use is associated with cancer, anemia, pain disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergic diseases such as rhinitis, conjunctivitis, dermatitis or food allergies, or bacterial infections such as green A lipocalin mutein for the method or use of any of the inventions 1010-1019, 1022 and 1023 for treating a Pseudomonas aeruginosa infection.
[Invention 1025]
A lipocalin mutein for the method or use of any of the inventions 1010-1024, wherein the onset of effect of the lipocalin mutein is faster than when the lipocalin mutein is administered subcutaneously.
[Invention 1026]
A lipocalin for the method, or use of any of the inventions 1010-1024, wherein the onset of effect of the lipocalin mutein is about as fast as or faster than when the lipocalin mutein is administered systemically. Mutein.
[Invention 1027]
1024. The method of any of the inventions 1010-1024, wherein the onset of effect of the lipocalin mutein in combination with FDKP is about as rapid as or faster than when the lipocalin mutein is administered alone by inhalation. , or lipocalin muteins for use.
[Invention 1028]
dosing is once, once a week, twice a week, three times a week, four times a week, five times a week, six times a week, once a day, twice a day; A lipocalin mutein for any of the foregoing methods, methods, or uses of the invention.
[Invention 1029]
A lipocalin mutein for any of the foregoing methods, methods, or uses of the invention wherein the lipocalin mutein is administered in nebulized form.
[Invention 1030]
A lipocalin mutein for any of the foregoing methods, methods, or uses of the invention wherein the lipocalin mutein is administered as a dry powder.
[Invention 1031]
A lipocalin mutein for any of the foregoing methods, methods, or uses of the invention wherein the lipocalin mutein is administered as a liquid spray.
[Invention 1032]
A lipocalin mutein for use in any of the foregoing inventions, wherein the lipocalin mutein is administered to a human subject.
[Invention 1033]
The method, or composition for use, of any of the preceding inventions, wherein the lipocalin mutein is a mutein of human tear lipocalin (hTlc) or human neutrophil gelatinase-associated lipocalin (hNGAL).
Claims (20)
(b)リポカリンムテインの全身曝露が検出不可能である
ように用いられることを特徴とする、請求項1記載の医薬。 (a) about 0.15% or less of the delivered dose of the lipocalin mutein enters the circulation, or
(b) undetectable systemic exposure to lipocalin muteins
2. The medicament according to claim 1 , characterized in that it is used as
(b)血漿中リポカリンムテインの最大濃度が、投与後約0.5時間～約10時間の時点で、もしくは投与後約0.5時間～約4時間の時点で実現される、または
(c)血漿中リポカリンムテインの最大濃度が、約1ng/mLもしくはそれより高く、または約1ng/mL～約2,000ng/mLである、
請求項7記載の医薬。 (a) about 0.3% or more, about 0.4% or more, about 0.5% or more, about 0.6% or more, about 0.7% or more, about 0.8% or more, about 0.9% or more, about 1% or more, about 2% or more, about 3% or more, about 4% or more, about 5% or more, about 6% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 11% or more more, about 12% or more, about 13% or more, about 14% or more, or about 15% or more enters the circulatory system,
(b) maximal plasma lipocalin mutein concentration is achieved from about 0.5 hours to about 10 hours after administration, or from about 0.5 hours to about 4 hours after administration, or
(c) a maximum plasma lipocalin mutein concentration of about 1 ng/mL or higher, or from about 1 ng/mL to about 2,000 ng/mL;
The medicament according to claim 7 .
(b)リポカリンムテインが、約2時間～約10時間の血清半減期(t 1/2 )を有する、または
(c)リポカリンムテインへの全身曝露が、同じまたは同程度の生体利用可能量のリポカリンムテインの全身投与と比べて改善された治療効果をもたらす
ように用いられることを特徴とする、請求項7～10のいずれか一項記載の医薬。 (a) the lipocalin mutein has an area under the curve of serum concentration over time (AUC inf ) of about 10 h*ng/mL or greater, or from about 10 h*ng/mL to about 16,000 h*ng/mL; be,
(b) the lipocalin mutein has a serum half-life (t 1/2 ) of from about 2 hours to about 10 hours, or
(c) systemic exposure to a lipocalin mutein confers an improved therapeutic effect compared to systemic administration of the same or similar bioavailable amount of the lipocalin mutein;
The medicament according to any one of claims 7 to 10 , characterized in that it is used as
(b)気道の疾患以外の、器官もしくは組織を冒す疾患の治療用である、
請求項7～11のいずれか一項記載の医薬。 (a) is for the treatment of a systemic disease, or
(b) for the treatment of diseases affecting organs or tissues other than diseases of the respiratory tract;
The medicament according to any one of claims 7-11 .
(b)リポカリンムテインの効果の発現が、リポカリンムテインが全身投与された場合の発現とほぼ同じ速さであるかもしくはそれよりも速い、または
(c)FDKPと組み合わせたリポカリンムテインの効果の発現が、リポカリンムテインが吸入によって単独で投与された場合の発現とほぼ同じ速さであるかもしくはそれよりも速い、
請求項7～15のいずれか一項記載の医薬。 (a) the onset of effect of the lipocalin mutein is faster than when the lipocalin mutein is administered subcutaneously;
(b) the onset of effect of the lipocalin mutein is about as rapid or faster than the onset when the lipocalin mutein is administered systemically, or
(c) the onset of effect of a lipocalin mutein in combination with FDKP is about as rapid or faster than when the lipocalin mutein is administered alone by inhalation;
The medicament according to any one of claims 7-15 .
(b)リポカリンムテインが乾燥粉末として投与される、または
(c)リポカリンムテインが液状スプレーとして投与される
ように用いられることを特徴とする、請求項1～17のいずれか一項記載の医薬。 (a) the lipocalin mutein is administered in nebulized form,
(b) the lipocalin mutein is administered as a dry powder, or
(c) the lipocalin mutein is administered as a liquid spray
The medicament according to any one of claims 1 to 17 , characterized in that it is used as
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826767P | 2019-03-29 | 2019-03-29 | |
| US62/826,767 | 2019-03-29 | ||
| EP19166435.8 | 2019-04-01 | ||
| EP19166435 | 2019-04-01 | ||
| EP19175818.4 | 2019-05-22 | ||
| EP19175818 | 2019-05-22 | ||
| EP19177568.3 | 2019-05-31 | ||
| EP19177568 | 2019-05-31 | ||
| EP19211404.9 | 2019-11-26 | ||
| EP19211404 | 2019-11-26 | ||
| PCT/EP2020/058637 WO2020201038A1 (en) | 2019-03-29 | 2020-03-27 | Inhaled administration of lipocalin muteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022526367A JP2022526367A (en) | 2022-05-24 |
| JPWO2020201038A5 true JPWO2020201038A5 (en) | 2023-04-03 |
Family
ID=70292935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557778A Withdrawn JP2022526367A (en) | 2019-03-29 | 2020-03-27 | Inhalation administration of lipocalin muthein |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220168387A1 (en) |
| EP (1) | EP3946417A1 (en) |
| JP (1) | JP2022526367A (en) |
| KR (1) | KR20210146999A (en) |
| CN (1) | CN113939307A (en) |
| AU (1) | AU2020253034A1 (en) |
| CA (1) | CA3127973A1 (en) |
| WO (1) | WO2020201038A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202241490A (en) * | 2020-12-18 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | Lipocalin mutein dry powder formulation for treatment of asthma |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| AU2003275958A1 (en) | 2003-08-25 | 2005-03-10 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| WO2006056464A2 (en) | 2004-11-26 | 2006-06-01 | Pieris Ag | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) |
| JP5608368B2 (en) | 2006-08-01 | 2014-10-15 | ピエリス アーゲー | Tear lipocalin mutein and method for obtaining the same |
| CN106986926A (en) | 2008-01-30 | 2017-07-28 | 皮里斯股份公司 | The mutain and its preparation method of tear lipocalin with the compatibility to people's C MET receptor tyrosine kinases |
| BR112012013662B1 (en) | 2009-12-07 | 2022-08-02 | Pieris Pharmaceuticals Gmbh | LIPOCALIN MUTEINS ASSOCIATED WITH HUMAN NEUTROPHIL GELATINASE (LCN2, HNGAL), THEIR USE AND THEIR GENERATION AND PRODUCTION METHODS, NUCLEIC ACID MOLECULE, HOST CELL, PHARMACEUTICAL COMPOSITION AND DIAGNOSIS OR ANALYTICAL KIT |
| WO2011154420A2 (en) | 2010-06-08 | 2011-12-15 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
| CN103154023B (en) | 2010-08-16 | 2017-04-05 | 皮里斯制药有限公司 | The associated proteins of hepcidin |
| DK2640740T3 (en) | 2010-11-15 | 2017-06-26 | Pieris Pharmaceuticals Gmbh | MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) |
| DK2646552T3 (en) | 2010-12-02 | 2017-10-23 | Pieris Pharmaceuticals Gmbh | MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4 |
| EP3309555A3 (en) | 2011-12-12 | 2018-05-30 | Pieris Pharmaceuticals GmbH | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| CN109432402B (en) | 2011-12-13 | 2022-04-29 | 皮里斯制药有限公司 | Methods for preventing or treating certain disorders by inhibiting IL-4 and/or IL-13 binding to their respective receptors |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US10526384B2 (en) | 2012-11-19 | 2020-01-07 | Pieris Pharmaceuticals Gmbh | Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof |
| CN105246503A (en) | 2013-03-14 | 2016-01-13 | 第一三共株式会社 | Novel binding proteins for pcsk9 |
| US10774119B2 (en) | 2014-05-22 | 2020-09-15 | Pieris Pharmaceuticals Gmbh | Specific-binding polypeptides and uses thereof |
| KR20170105609A (en) | 2015-01-28 | 2017-09-19 | 피어이스 파마슈티컬즈 게엠베하 | Novel proteins specific for angiogenesis |
| TN2017000348A1 (en) | 2015-02-18 | 2019-01-16 | Sanofi Sa | Novel proteins specific for pyoverdine and pyochelin |
| DK3292137T3 (en) | 2015-05-04 | 2022-10-17 | Pieris Pharmaceuticals Gmbh | PROTEINS SPECIFIC FOR CD137 |
| US10273275B2 (en) | 2015-05-18 | 2019-04-30 | Pieris Pharmaceuticals Gmbh | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof |
| US10501510B2 (en) | 2015-07-15 | 2019-12-10 | Pieris Pharmaceuticals Gmbh | Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof |
| TW201725212A (en) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | Novel proteins specific for calcitonin gene-related peptide |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CN110402252A (en) | 2017-01-18 | 2019-11-01 | 皮里斯制药有限公司 | There is the lipocalin mutein albumen of binding affinity to LAG-3 |
-
2020
- 2020-03-27 KR KR1020217035440A patent/KR20210146999A/en unknown
- 2020-03-27 JP JP2021557778A patent/JP2022526367A/en not_active Withdrawn
- 2020-03-27 EP EP20719569.4A patent/EP3946417A1/en active Pending
- 2020-03-27 WO PCT/EP2020/058637 patent/WO2020201038A1/en unknown
- 2020-03-27 CA CA3127973A patent/CA3127973A1/en active Pending
- 2020-03-27 CN CN202080025546.6A patent/CN113939307A/en active Pending
- 2020-03-27 AU AU2020253034A patent/AU2020253034A1/en not_active Abandoned
- 2020-03-27 US US17/599,765 patent/US20220168387A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6616914B2 (en) | Method for pulmonary and oral delivery of pharmaceuticals | |
| ES2780127T3 (en) | Superfine Formoterol Formulation | |
| US10596146B2 (en) | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders | |
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| US10391078B2 (en) | Methods for the treatment of mast cell related disorders with mast cell stabilizers | |
| Douafer et al. | Scope and limitations on aerosol drug delivery for the treatment of infectious respiratory diseases | |
| ES2809177T3 (en) | Inhalation of levofloxacin to reduce lung inflammation | |
| JP2021193091A (en) | Intranasal epinephrine preparations and methods for treatment of disease | |
| JP2023086774A (en) | Dry powder compositions and methods of use | |
| JP2017509684A5 (en) | ||
| KR20100091970A (en) | Compositions for treating parkinson's disease | |
| JPH0648958A (en) | Anti-reactive and anti-asthmatic activity of non-steroid anti-phlogistic agent based on inhalation | |
| JP2774379B2 (en) | Pharmaceutical aerosol compositions and their use in treating and preventing viral diseases | |
| WO2018017434A1 (en) | Methods for treating cystic fibrosis and other diseases affecting mucosal surfaces | |
| Kaur et al. | Advanced aerosol delivery devices for potential cure of acute and chronic diseases | |
| WO2021212183A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing microbial infections | |
| Beck-Broichsitter et al. | Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension | |
| IT202000005026A1 (en) | Lactoferrin for inhalation use with antiviral action | |
| Sheikh et al. | Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment? | |
| Yue et al. | Inhaled drug delivery: Past, present, and future | |
| CN106667974A (en) | Preparation method of terbutaline sulfate solution for inhalation | |
| JPWO2020201038A5 (en) | ||
| JP2023551989A (en) | Product delivery devices and methods | |
| JP2019516797A5 (en) | ||
| WO2020132263A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders |